Anti-Coagulants - Australia

Australia

In Australia, the Anti-Coagulants market is expected to experience significant growth in the coming years.
By 2024, the projected revenue in this market is estimated to reach US$311.40m.
This indicates a positive trend in the demand for anti-coagulant products within the country.
Looking ahead, the market is predicted to continue expanding at an annual growth rate of 7.95% from 2024 to 2028.
This steady growth trajectory is anticipated to result in a market volume of US$422.90m by 2028, further solidifying the importance of the Anti-Coagulants market in Australia.
When compared globally, it is worth noting that United States is expected to dominate the revenue generation in the Anti-Coagulants market.
With an estimated revenue of US$16,740.00m in 2024, United States will hold a significant share of the global market.
This highlights the strong presence and market potential of anti-coagulant products United States, while also emphasizing the competitive nature of the industry on a global scale.
Australia's growing elderly population is driving an increased demand for anti-coagulants in the country.

Key regions: Germany, South Korea, France, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Australia has been steadily growing over the past few years, driven by several factors that have contributed to an increase in demand for these medications.

Customer preferences: One of the main factors driving the growth of the Anti-Coagulants market in Australia is the aging population. As people age, they become more susceptible to a range of health issues, including blood clots, which can lead to serious complications such as stroke or heart attack. As a result, there has been an increased demand for Anti-Coagulants medications among older Australians.

Trends in the market: Another trend that has contributed to the growth of the Anti-Coagulants market in Australia is the increasing prevalence of lifestyle diseases such as obesity and diabetes. These conditions can increase the risk of blood clots, and as a result, more Australians are turning to Anti-Coagulants medications to manage their health.

Local special circumstances: One of the unique aspects of the Anti-Coagulants market in Australia is the country's healthcare system, which is a mix of public and private providers. This has led to a situation where different medications are available through different channels, with some drugs only available to patients who can afford to pay for them out of pocket.

Underlying macroeconomic factors: Overall, the growth of the Anti-Coagulants market in Australia can be attributed to a combination of demographic, lifestyle, and healthcare factors. As the population continues to age and lifestyle diseases become more prevalent, the demand for these medications is likely to continue to increase in the coming years. However, the availability of different medications through different channels could create challenges for patients and healthcare providers alike.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.